Insiders Trades
SI-BONE, Inc. Stock: price and insider trades · United States
SI-BONE, Inc.: what insiders have been doing
SI-BONE, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 79 filings came from 12 insiders.
No insider bought on the market over the period, while 7 insiders filed 57 sales totalling €5.9M. At €864k, the sale published on 21 August 2026 by Francis Laura is the largest of the period (0.12% of market cap).
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 79 filings, this issuer sits above that mark. The full history, which starts in 2021, counts no purchases against 203 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 200.9 m USD and net income of -18.9 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
297
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€13M
203 ops. · all time
Who traded when
BuySaleAnshul Maheshwari27 sales
Michael A. Pisetsky18 sales
Laura Francis17 sales
Jeffrey W. Dunn15 sales
Recupero Anthony J11 sales
Davis Timothy E JR2 sales
+3 other insiders
Analyst consensus: bullish or bearish?
Analysts rate SI-BONE, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$25.44.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,973 of 24,148 companies
35.1
score / 100
Value29
Quality41
FCF yld-1.1%
Earn yld-2.2%
EV/EBITDA·
ROE-8.3%
Gross mgn80%
Net mgn-9.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.47
Analyst consensus
9 analystsStrong buy
US$20.00Target US$25.44(+31%)US$32.00
Income statement
RevenueUS$200.9M
Gross profitUS$159.9M80% margin
EBITDA-US$10.5M-5% margin
Net income-US$18.9M-6.9% margin
Valuation
PER (forward)-58.9x
P/Book4.8x
Beta0.66
Balance sheet & cash
Market capUS$863.5M
Total debtUS$36.7M
Free Cash Flow-US$9.1M
Debt / Equity23%
Profitability & ownership
ROE-8.3%
ROA-4.6%
% insiders3.2%
% institutions109.6%
Last declaration on 14 October 2026
Declarations297 total
38,006 shares@ US$20.04980.085% mcap18.2% of flowCommon StockSEC:0001218802-26-000006:0
38,006 shares@ US$19.370.083% mcap32.0% of flowCommonSEC144:0001950047-26-010155
1,799 shares@ US$18.14180.0038% mcap4.8% of flowCommon StockSEC:0001754765-26-000007:1
1,300 shares@ US$18.20330.0028% mcap3.5% of flowCommon StockSEC:0001754765-26-000007:0
34 shares@ US$18.140.0001% mcap0.1% of flowCommon StockSEC:0001754765-26-000007:2
1,560 shares@ US$18.16740.0033% mcap1.5% of flowCommon StockSEC:0001853089-26-000009:0
1,758 shares@ US$18.19330.0038% mcap1.6% of flowCommon StockSEC:0001853089-26-000009:1
1,731 shares@ US$19.500.0040% mcap1.7% of flowCommon StockSEC:0001853089-26-000009:2
1,731 shares@ US$18.080.0037% mcap5.5% of flowCommonSEC144:0001950047-26-010051
20,000 shares@ US$4.680.011% mcap1.9% of flowCommon StockSEC:0001035986-26-000007:0
20,000 shares@ US$18.470.043% mcap7.6% of flowCommon StockSEC:0001035986-26-000007:1
18,633 shares@ US$4.680.010% mcap1.9% of flowCommon StockSEC:0001035986-26-000006:0
1,367 shares@ US$4.680.0008% mcap0.1% of flowCommon StockSEC:0001035986-26-000006:1
18,633 shares@ US$18.9080.042% mcap7.8% of flowCommon StockSEC:0001035986-26-000006:2
1,367 shares@ US$18.9080.0031% mcap0.6% of flowCommon StockSEC:0001035986-26-000006:3
25,972 shares@ US$20.12150.062% mcap14.6% of flowCommon StockSEC:0001218802-26-000005:0
25,972 shares@ US$19.960.061% mcap100.0% of flowCommonSEC144:0001950047-26-008595
11,636 shares@ US$19.960.028% mcap41.3% of flowCommonSEC144:0001950047-26-008605
3,923 shares@ US$19.480.0091% mcap6.9% of flowCommonSEC144:0001950047-26-008557
11,228 shares@ US$19.480.026% mcap38.9% of flowCommonSEC144:0001950047-26-008520
5,747 shares@ US$19.550.013% mcap5.9% of flowCommon StockSEC:0001853089-26-000007:0
51,884 shares@ US$19.460.12% mcap28.2% of flowCommon StockSEC:0001218802-26-000004:0
3,923 shares@ US$20.020.0093% mcap2.2% of flowCommon StockSEC:0001218802-26-000004:1
11,228 shares@ US$20.020.027% mcap11.7% of flowCommon StockSEC:0001853089-26-000007:1
51,884 shares@ US$19.910.12% mcap93.1% of flowCommonSEC144:0001950047-26-008468
25 of 297 declarations
About SI-BONE, Inc.
SI-BONE, Inc. is a U.S.-based medical device company listed on the Nasdaq in the United States. The company focuses on sacropelvic and musculoskeletal disorders, with a particular emphasis on sacroiliac (SI) joint dysfunction and related fusion procedures. Founded in 2008 in Delaware and headquartered in Santa Clara, California, SI-BONE built its franchise around a clinically differentiated implant platform and a strong evidence-based positioning in a niche segment of orthopedic surgery. Its early leadership came from the iFuse system, a minimally invasive, triangular implant designed for SI joint fusion, which helped establish the company as an early mover in this category. ([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai))
From an operating perspective, SI-BONE sells procedural solutions to surgeons, hospitals, and ambulatory care providers, rather than operating as a broad orthopedic conglomerate. Its product portfolio now extends beyond the original iFuse platform and includes iFuse-3D, iFuse TORQ, iFuse Bedrock Granite, and iFuse INTRA, among others. This line expansion is important strategically: management has been repositioning the company from a single-product story toward a broader “compromised bone” solutions platform that can address additional clinical use cases in the pelvis, trauma, and spine-adjacent segments. ([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai))
Read moreShow less
Competitively, SI-BONE’s moat is based on first-mover advantage, a long clinical track record, surgeon education, and the company’s accumulated regulatory and reimbursement experience. In a specialty market where physician adoption and payer coverage are critical, SI-BONE has emphasized published clinical data, FDA clearances, and continued product iteration as sources of differentiation. The business remains primarily U.S.-driven, but it has also been expanding internationally, including launches in Europe and broader commercial activity outside the U.S. ([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-announces-publication-5-year-follow-data-ifuse?utm_source=openai))
Recent developments have been supportive of the growth narrative. In 2025, SI-BONE reported strong revenue growth and highlighted improving profitability metrics, alongside favorable reimbursement progress. The company also continued to broaden its portfolio with new product launches and line extensions, while announcing a distribution agreement with Smith+Nephew to improve market access for certain solutions. For equity investors, SI-BONE is best viewed as an innovation-led, specialty medtech company with a focused franchise, a growing international footprint, and multiple execution catalysts tied to product adoption, reimbursement, and commercial expansion. ([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-reports-record-financial-results-fourth-quarter-2025/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
